BI
BIOCQ.US Biocept Inc.
- Market cap
- USD 525.00
- P/E
- -
- P/B
- 0.29x
- ROE
- -7,431.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is BIOCQ.US undervalued?
Graham numberThe Graham number of Biocept Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biocept Inc. fundamental analysis
No fundamental analysis for Biocept Inc. yet.
Biocept Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biocept Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resis…
Full company profileBiocept Inc. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biocept Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 5.53M | 27.5M | 61.2M | 25.9M | 2.52M |
| Gross Profit | -5.45M | 6.12M | 23.5M | -2.58M | -8.63M |
| Operating Income | -23.1M | -15.5M | -2.41M | -32.0M | -26.4M |
| EBITDA | -24.1M | -16.6M | 228K | -30.2M | -19.4M |
| Net Income | -25.1M | -17.8M | -2.82M | -32.1M | -21.6M |
| EPS | -365 | -45 | -5.73 | -57 | -21 |
| Balance Sheet | |||||
| Total Assets | 17.7M | 47.5M | 60.4M | 30.9M | 22.1M |
| Total Liabilities | 6.53M | 23.8M | 22.9M | 22.0M | 21.8M |
| Shareholders' Equity | 11.2M | 23.7M | 37.5M | 8.86M | 290K |
| Cash & Short-term Investments | 9.30M | 14.4M | 28.9M | 12.9M | 6.63M |
| Total Debt | 2.54M | 12.2M | 12.7M | 12.1M | 11.6M |
| Cash Flow | |||||
| Operating Cash Flow | -23.0M | -19.8M | 3.69M | -13.3M | -18.6M |
| Capital Expenditure | 735K | 867K | 1.57M | 807K | 376K |
| Free Cash Flow | -23.8M | -20.7M | 2.12M | -14.1M | -18.9M |
| Ratios | |||||
| ROE | -224.4% | -75.2% | -7.5% | -362.2% | -7,431.0% |
| ROA | -141.8% | -37.5% | -4.7% | -103.9% | -97.5% |
| Net Profit Margin | -454.7% | -64.8% | -4.6% | -124.1% | -853.8% |
| Debt to Equity | 0.23x | 0.52x | 0.34x | 1.37x | 39.97x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biocept Inc. dividends
Biocept Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:30 on May 17, 2023.
Who owns Biocept Inc.
Ownership data of Biocept Inc. is not available yet.
Biocept Inc. company profile
- Company name
- Biocept Inc.
- Ticker
- BIOCQ.US
- Exchange
- USA Stocks
- Listed since
- Feb 25, 2005
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 50
- Fiscal year end
- December
- Address
- 9955 Mesa Rim Road, San Diego, CA, United States, 92121
- Phone
- 858 320 8200
- Website
- biocept.com
About Biocept Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Biocept Inc. management
3- Dr. Soon Kap Hahn Ph.D.Founder
- Mr. Pavel TsinbergDirector of Technology Development
- Dr. Veena M. SinghSenior Medical Director · born 1975